Drugs / S-Amlodopine
S-Amlodopine
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05843162 Background | Jun → Dec 2023 | essential hypertension, metabolic syndrome X | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S-Amlodopine | “Subjects assigned to the test group are oral administered Telmisartan 40 mg and S-Amlodopine 2.5 mg once a day for 12 weeks.” NCT05843162 ↗ |
| Known as | Anydipine-S | “Telmitrend Tab.(Telmisartan) 40mg(80mg) + Anydipine-S(S-amlodipine) Tab. 2.5mg” NCT05843162 ↗ |
| Known as | S-amlodipine | “Telmitrend Tab.(Telmisartan) 40mg(80mg) + Anydipine-S(S-amlodipine) Tab. 2.5mg” NCT05843162 ↗ |
| Route | Oral | “Subjects assigned to the test group are oral administered Telmisartan 40 mg and S-Amlodopine 2.5 mg once a day for 12 weeks.” NCT05843162 ↗ |